BioCardia Files 8-K for Common Stock & Warrant Agreements
Ticker: BCDA · Form: 8-K · Filed: Jan 3, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: capital-raise, equity-offering, warrants, dilution
TL;DR
**BioCardia just filed an 8-K for new stock and warrant agreements, likely diluting shares to raise cash.**
AI Summary
BioCardia, Inc. filed an 8-K on January 3, 2024, to disclose that it has entered into a Common Stock Purchase Agreement and a Warrant to Purchase Common Stock Agreement. This filing indicates that the company is likely raising capital through the issuance of new shares and warrants. For investors, this means potential dilution of existing shares, which could impact the stock price, but it also suggests the company is securing funds for its operations or future projects.
Why It Matters
This filing signals BioCardia is raising capital, which could dilute existing shareholders but also provides necessary funding for the company's operations and growth initiatives.
Risk Assessment
Risk Level: medium — The issuance of new common stock and warrants typically leads to dilution for existing shareholders, which can negatively impact share price.
Analyst Insight
A smart investor would monitor the details of the Common Stock Purchase Agreement and Warrant to Purchase Common Stock Agreement, once available, to assess the extent of dilution and the terms of the capital raise, and consider if the new capital sufficiently funds growth to offset dilution.
Key Players & Entities
- BioCardia, Inc. (company) — the registrant filing the 8-K
- Common Stock (other) — securities being issued
- Warrant to Purchase Common Stock (other) — securities being issued
- January 3, 2024 (date) — date of earliest event reported
Forward-Looking Statements
- BioCardia will experience short-term stock price volatility due to potential dilution concerns. (BioCardia, Inc.) — medium confidence, target: 2024-03-31
FAQ
What is the primary purpose of BioCardia, Inc.'s 8-K filing on January 3, 2024?
The primary purpose of BioCardia, Inc.'s 8-K filing on January 3, 2024, is to report the entry into a Common Stock Purchase Agreement and a Warrant to Purchase Common Stock Agreement, as indicated by the 'ITEM INFORMATION: Regulation FD Disclosure' and the specific mention of these agreements in the filing.
What types of securities are involved in the agreements reported in this 8-K?
The agreements reported in this 8-K involve 'Common Stock' and 'Warrant to Purchase Common Stock', as explicitly stated in the filing under the relevant sections.
What is BioCardia, Inc.'s business address as listed in the filing?
BioCardia, Inc.'s business address is 320 Soquel Way, Sunnyvale, California 94085, according to the 'BUSINESS ADDRESS' section of the filing.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (650) 226-0120, as stated in the filing.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 3, 2024, as indicated by 'Date of Report (Date of earliest event reported): January 3, 2024'.
Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-03 07:00:18
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Warrant
Filing Documents
- bcda20240102_8k.htm (8-K) — 28KB
- ex_611509.htm (EX-99.1) — 15KB
- 0001437749-24-000289.txt ( ) — 192KB
- bcda-20240103.xsd (EX-101.SCH) — 4KB
- bcda-20240103_def.xml (EX-101.DEF) — 13KB
- bcda-20240103_lab.xml (EX-101.LAB) — 17KB
- bcda-20240103_pre.xml (EX-101.PRE) — 13KB
- bcda20240102_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.   On January 3, 2024, BioCardia, Inc. (the "Company") issued a press release containing a letter to shareholders, which provides an update on business development related to its biotherapeutic delivery and Morph Access Innovations businesses. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.   The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.   
01     Financial Statements and Exhibits
Item 9.01     Financial Statements and Exhibits.   (d) Exhibits   Exhibit No.   Description 99.1 104   BioCardia, Inc. press release dated January 3, 2024 Cover Page Interactive Data File (embedded within the Inline XBRL document)        
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     BIOCARDIA, INC.       /s/ Peter Altman, Ph.D.   Peter Altman, Ph.D.   President and Chief Executive Officer       Date: January 3, 2024